Business Wire

SEOUL-SEMICONDUCTOR

24.5.2017 09:09:07 CEST | Business Wire | Press release

Share
Seoul Semiconductor Continuously Pursues patent infringement actions against Everlight products

Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) — On April 28, 2017, Seoul Semiconductor Europe GmbH (“Seoul”) filed a patent infringement claim in Germany at the District Court of Düsseldorf against Mouser Electronic Inc. (“Mouser), a global electronic components distributor, which it accused of selling Everlight LED products.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005266/en/

In its complaint, Seoul asserted that Everlight’s Mid-Power LED products are infringing Seoul’s patent rights. Seoul has sought a permanent injunction, damages, and recall and destruction of the allegedly infringing products.

The asserted patent serves to improve the light extraction performance of LED devices by enhancing internal-reflection efficiency, which has been widely used in mid-power and high-power LEDs.

This patent litigation is the second patent infringement litigation by Seoul or its affiliate affecting Everlight’s LED products. In March 2017, Seoul Semiconductor Co., Ltd. filed a patent infringement claim in Germany, accusing high-power LED products manufactured by Everlight as well as other LED manufacturers. These patent litigations underscore Seoul’s commitment to protecting its intellectual property rights against infringement, including products consisting of mid-power LEDs and high-power LEDs.

In addition to Seoul’s patent infringement actions, Everlight has been implicated in other patent infringement lawsuits as described below. Nam Ki-bum, Vice President of the Research Center at Seoul, said, “Several LED companies have grown rapidly in a short period of time despite a lack of valuable patent portfolios, which is like building a castle on quicksand. There is no underlying foundation for the company’s products. Seoul, however, has been investing 10% of its revenue in research and development for many years to develop innovative technology and strengthen our patent portfolio. To support a fair market that respects intellectual property rights, Seoul will continuously monitor and take action against alleged infringers in any countries where infringement occurs.”

* Reference [source: various media news articles]

Plaintiff   Defendant   Business Relation   Patented Technology   Courts   State   Link
Nichia   WOFI Leuchten   Everlight subsidiary   phosphor   Düsseldorf District Court, Germany   Nichia won the suit in the court of first instance and the court ruled for an injunction  

http://www.ledinside.com/news/2016/12
/nichia_clinches_two_legal_victories_ag
ainst_everlight_in_german_district_court
s

http://www.nichia.co.jp/en/about_nichia/2
016/2016_122102.html

Nichia   REGO-Lighting   Used a white LED tube light product by Everlight subsidiary Zenar   phosphor   Düsseldorf District Court, Germany   On Dec. 5, 2016, the appeals court confirmed patent infringement and ruled in favor of Nichia.  

http://www.nichia.co.jp/en/about_nichia/2
016/2016_122101.html

http://www.ledinside.com/news/2016/12/
nichia_clinches_two_legal_victories_aga
inst_everlight_in_german_district_courts

Nichia   Everlight   Everlight   phosphor   Düsseldorf District Court, Germany   On Oct. 24, 2016, the court granted a preliminary injunction.  

http://www.nichia.co.jp/en/about_nichia/2
016/2016_111701.html

http://www.ledinside.com/news/2016/11/
german_court_grants_nichia_preliminary
_injunctions_for_white_led_products_that
_infringed_patents

Nichia   Tachibana Eletech and E&E Japan   Distributor of blue LEDs manufactured by Everlight in Japan   LED chip   Tokyo District Court, Japan   On Oct. 14, 2016, the court issued an oder ruled for an infringement in favor of Nichia.  

http://www.nichia.co.jp/en/about_nichia/2016
/2016_102001.html

http://www.ledinside.com/press/2016/10/nich
ia_wins_patent_infringement_lawsuit_agains
t_tachibana_and_ee_japan_in_tokyo

Nichia   Mouser   Distributor of Everlight products   phosphor   Düsseldorf District Court, Germany   On Oct. 7, 2016, the court granted a preliminary injunction.  

http://www.nichia.co.jp/en/about_nichia/2
016/2016_101301.html

http://www.ledinside.com/news/2016/10/g
erman_court_grants_preliminary_injunctio
n_against_mouser_based_on_nichia_yag
_patent

Nichia   Everlight   Everlight   LED Package   The U.S. District Court for the Eastern District of Texas   The Federal Circuit affirmed an infringement of Nichia’s patents.  

http://www.nichia.co.jp/en/about_nichia/20
17/2017_050901.html

http://www.ledinside.com/news/2017/5/nic
hia_wins_important_victory_in_federal_ci
rcuit_appeal

Nichia   EBV Elektronik GmbH & Co. KG and EBV Management GmbH (both “EBV“)   Distributor of Everlight products   phosphor   Düsseldorf District Court, Germany   Still in progress  

http://www.nichia.co.jp/en/about_nichia
/2017/2017_030802.html

http://www.ledinside.com/press/2017/3/nichia

_files_patent_infringement_lawsuit_against_

ebv_in_germany_regarding_white_led_

product_of_everlight

Nichia   Everlight Electronics (China) and Beijing Ducheng Yiguang Electronic Devices Selling Center   Everlight subsidiary   phosphor   Beijing Intellectual Property Court, China   Still in progress  

http://www.nichia.co.jp/en/about_nichia
/2016/2016_032401.html

http://www.ledinside.com/news/2016/3/
nichia_files_new_led_patent_infringem
ent_lawsuits_respectively_in_china_an
d_us

Seoul Semiconductor   Mouser   Distributor of Everlight products   High Power LED   Düsseldorf District Court, Germany   Still in progress  

http://www.ledinside.com/news/2017/4/se
oul_semiconductor_files_patent_infringe
ment_lawsuit_in_germany

Seoul Semiconductor   Mouser   Distributor of Everlight products   Mid Power LED   Düsseldorf District Court, Germany   On April 28, 2017, Seoul filed the lawsuit.    
           

About Seoul Semiconductor:

Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fifth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured Package-Free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's leading direct AC LED; Acrich MJT multi-junction technology; a proprietary family of high-voltage LEDs; NanoDriver Series – World’s Smallest 24W DC LED Drivers and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs.

For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com

# Trademarks: Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.

Contact:

Asia
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Email: pr@seoulsemicon.com
or
Europe
Seoul Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Email: press.eu@seoulsemicon.com
or
North America
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
Email: David.cox@seoulsemicon.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye